Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

Group 1 - Madrigal reported a quarterly loss of $3.32 per share, better than the Zacks Consensus Estimate of a loss of $3.62, and an improvement from a loss of $7.38 per share a year ago, representing an earnings surprise of 8.29% [1] - The company posted revenues of $137.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 20.35%, compared to zero revenues a year ago [2] - Madrigal shares have increased approximately 8.2% since the beginning of the year, while the S&P 500 has declined by 5.3% [3] Group 2 - The current consensus EPS estimate for the coming quarter is -$3.31 on revenues of $137.59 million, and -$12.43 on revenues of $576.53 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 23% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] Group 3 - The estimate revisions trend for Madrigal is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]